iRadimed (NASDAQ:IRMD) Cut to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen downgraded iRadimed from “Buy” to “Hold,” followed by a similar downgrade from Weiss Ratings. Despite this, analysts maintain a “Moderate Buy” consensus with an average price target of $120.
• iRadimed recently exceeded quarterly expectations, reporting $0.46 EPS versus the $0.44 estimate and revenue of $20.47 million versus $20.35 million expected. Shares opened at $92.50, with a market capitalization of approximately $1.18 billion.
• CEO Roger E. Susi sold 5,000 shares under a pre-arranged trading plan, and insiders have sold 17,500 shares worth about $1.52 million over the past quarter. Institutional investors own 92.34% of the company.

iRadimed (NASDAQ:IRMD - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Saturday.

Separately, Weiss Ratings downgraded iRadimed from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $120.00.

iRadimed Trading Up 1.4%

Shares of NASDAQ:IRMD opened at $92.50 on Friday. The stock has a market capitalization of $1.18 billion, a PE ratio of 51.68 and a beta of 0.90. iRadimed has a 1 year low of $67.84 and a 1 year high of $107.90. The firm has a fifty day moving average price of $94.55 and a 200 day moving average price of $95.40.

iRadimed (NASDAQ:IRMD - Get Free Report) last posted its earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.02. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.The company had revenue of $20.47 million for the quarter, compared to analyst estimates of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, sell-side analysts forecast that iRadimed will post 1.52 earnings per share for the current fiscal year.

Insider Buying and Selling

In other iRadimed news, CEO Roger E. Susi sold 5,000 shares of the business's stock in a transaction on Monday, May 18th. The shares were sold at an average price of $87.51, for a total transaction of $437,550.00. Following the completion of the transaction, the chief executive officer owned 2,175,000 shares of the company's stock, valued at $190,334,250. The trade was a 0.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 17,500 shares of company stock valued at $1,515,065. Company insiders own 34.60% of the company's stock.

Hedge Funds Weigh In On iRadimed

A number of institutional investors have recently made changes to their positions in the business. Quarry LP bought a new stake in iRadimed during the 3rd quarter valued at approximately $40,000. Farther Finance Advisors LLC increased its position in iRadimed by 827.1% in the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider's stock worth $43,000 after buying an additional 397 shares during the period. Tower Research Capital LLC TRC increased its position in iRadimed by 191.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider's stock worth $45,000 after buying an additional 495 shares during the period. CWM LLC lifted its holdings in shares of iRadimed by 19.5% during the fourth quarter. CWM LLC now owns 657 shares of the medical equipment provider's stock worth $64,000 after buying an additional 107 shares during the last quarter. Finally, Global Retirement Partners LLC acquired a new position in shares of iRadimed during the second quarter worth approximately $84,000. 92.34% of the stock is currently owned by institutional investors.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source